19. ~~28~~. The method of Claim ~~22~~ 13, wherein the compound is selected from the group consisting of Val^8-GLP-1(7-37), Gly^8-GLP-1(7-37), GLP-1(7-37), and GLP-1(7-36)NH_2.

~~20. 29~~. A method of reducing morbidity and mortality after myocardial infarction, comprising, administering to a patient in need thereof a compound that exerts insulinotropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity at a dose effective to normalize blood glucose.

Cancel C2

21. ~~30~~. A method of reducing morbidity and mortality after myocardial infarction, comprising, administering to a patient in need thereof a compound that enhances insulin sensitivity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in enhancing insulin sensitivity at a dose effective to normalize blood glucose.

Cancel C3

Add C3

Remarks

Support for these claims can be found throughout the Specification. For example, GLP-1 analogs and derivatives are defined and exemplified on page 6 through 12. Buffers and preservatives are discussed on page 20, lines 10 through 22. Discussion of the acute phase of myocardial infarction and treatment thereof is discussed beginning on the bottom on page 21 through page 22, line 16. GLP-1 derivatives and acylation of ε-amino groups are discussed on page 7 lines 8 through 12. Discussion of GLP-1s complexed with divalent metal cations can be found on page 20, lines 3 through 9. The preservatives meta-cresol and phenol are discussed on page 20, lines 16 through 18. Specific compounds encompassed by Claim 28 are disclosed on page 10, lines 1 through 7. The biological activities of GLP-1 such as those specified in Claims 29 and 30 are discussed on page 4, lines 7 through 31. Further Claims

29 and 30 correspond to originally filed Claims 12 and 13 in the parent application.

Respectfully submitted,

Mark J. Stewart

Mark J. Stewart, Ph.D.
Attorney for Applicant
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

April 12, 2001